Samsung Biologics Co Ltd
KRX:207940
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Samsung Biologics Co Ltd
KRX:207940
|
KR |
|
Taikisha Ltd
F:75L
|
JP |
Intrinsic Value
The intrinsic value of Samsung Biologics Co Ltd (207940) under the Base Case is 560 005.37 KRW per share.
Compared with the current market price of 1 452 000 KRW, the stock appears
Overvalued by 61% .
The intrinsic value is calculated using the DCF method. The model assumes Samsung Biologics' revenue grows about 13% a year over the next five years, less than half its five-year historical pace of 31%. Net margin stays near 34%, above its five-year average of 28%.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Samsung Biologics Does
Samsung Biologics is a contract developer and manufacturer of biologic medicines, which are drugs made from living cells rather than simple chemicals. It builds the processes needed to make these medicines, runs large-scale production for other drug companies, and also helps with development work such as cell line creation, process design, and quality testing. Its customers are mainly global pharmaceutical and biotechnology firms that need specialized factory capacity and technical know-how without building those facilities themselves.
- Headquarters
- Korea KR
- IPO date
- Nov 10, 2016
Revenue & Expenses Breakdown
Samsung Biologics Co Ltd
Earnings Waterfall
Samsung Biologics Co Ltd
The intrinsic value for Samsung Biologics Co Ltd (207940) under the Base Case is 560 005.37 KRW.
Compared with the current market price of 1 452 000 KRW, the stock appears Overvalued by 61% .